Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia.

Sanford, D; Kyle, R; Lazo-Langner, A; Xenocostas, A; Chin-Yee, I; Howson-Jan, K; Hsia, C.

Afiliação

Sanford D; Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON. ; Department of Medicine, Division of Hematology, London Health Sciences Centre, University of Western Ontario, London, ON.
Kyle R; Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON.
Lazo-Langner A; Department of Medicine, Division of Hematology, London Health Sciences Centre, University of Western Ontario, London, ON. ; Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON.
Xenocostas A; Department of Medicine, Division of Hematology, London Health Sciences Centre, University of Western Ontario, London, ON.
Chin-Yee I; Department of Medicine, Division of Hematology, London Health Sciences Centre, University of Western Ontario, London, ON.
Howson-Jan K; Department of Medicine, Division of Hematology, London Health Sciences Centre, University of Western Ontario, London, ON.
Hsia C; Department of Medicine, Division of Hematology, London Health Sciences Centre, University of Western Ontario, London, ON.

Curr Oncol ; 21(2): e241-9, 2014 Apr.

Article em En | MEDLINE | ID: mdl-24764709